MedMira Inc.
Research MedMira Inc. (MIR.V) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerMIR.V
- ExchangeV
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCAD
- Financial periodQ2 2026
- RevenueCAD 241.19K
- Net income-CAD 483.66K
- Free cash flow-CAD 150.63K
- Gross margin73.1%
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 232.99K | -CAD 4.04M | -CAD 2.41M | 69.7% | n/a | CAD 0 | CAD 9.57M | -CAD 23.37M |
About MedMira Inc.
MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What does MedMira Inc. do?
MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis.